SAREPTA THERAPEUTICS

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Nov 2022 15:00:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

28 Nov 2022 04:00:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference

23 Nov 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments

02 Nov 2022 13:05:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Oct 2022 15:00:31 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results

26 Oct 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022

07 Oct 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Sep 2022 15:15:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy

29 Sep 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027

14 Sep 2022 04:00:25 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027

12 Sep 2022 13:41:31 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year

07 Sep 2022 05:30:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

06 Sep 2022 05:45:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

06 Sep 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Aug 2022 14:59:49 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases

08 Aug 2022 05:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments

02 Aug 2022 13:05:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 Jul 2022 15:25:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy

29 Jul 2022 04:00:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022

26 Jul 2022 05:30:00 By Nasdaq GlobeNewswire